NZ546303A - Methods and compositions for treating herpes infections - Google Patents

Methods and compositions for treating herpes infections

Info

Publication number
NZ546303A
NZ546303A NZ546303A NZ54630304A NZ546303A NZ 546303 A NZ546303 A NZ 546303A NZ 546303 A NZ546303 A NZ 546303A NZ 54630304 A NZ54630304 A NZ 54630304A NZ 546303 A NZ546303 A NZ 546303A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
herpes
igg
composition
prepared
Prior art date
Application number
NZ546303A
Other languages
English (en)
Inventor
Ulrich Betz
Klaus-Peter Radtke
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Publication of NZ546303A publication Critical patent/NZ546303A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ546303A 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections NZ546303A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
PCT/US2004/028559 WO2005025617A2 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Publications (1)

Publication Number Publication Date
NZ546303A true NZ546303A (en) 2009-03-31

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ546303A NZ546303A (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Country Status (13)

Country Link
US (3) US6984492B2 (enExample)
EP (1) EP1663309A2 (enExample)
JP (1) JP2007504268A (enExample)
KR (1) KR20060107509A (enExample)
CN (1) CN1845756A (enExample)
AU (1) AU2004272001A1 (enExample)
BR (1) BRPI0414139A (enExample)
CA (1) CA2537360A1 (enExample)
IL (1) IL173805A0 (enExample)
NO (1) NO20061184L (enExample)
NZ (1) NZ546303A (enExample)
WO (2) WO2005023303A1 (enExample)
ZA (1) ZA200602738B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2248825T3 (pl) 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
WO2014070786A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
RU2703903C2 (ru) * 2014-06-26 2019-10-22 Хайдельберг Иммунотерапьютикс Гмбх Местное применение антитела к hsv
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020097528A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
WO1998046240A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
JP2007504268A (ja) 2007-03-01
BRPI0414139A (pt) 2006-10-31
CN1845756A (zh) 2006-10-11
US6984492B2 (en) 2006-01-10
KR20060107509A (ko) 2006-10-13
US20090232798A1 (en) 2009-09-17
US20060198848A1 (en) 2006-09-07
WO2005025617A2 (en) 2005-03-24
WO2005025617A3 (en) 2005-05-26
CA2537360A1 (en) 2005-03-24
IL173805A0 (en) 2006-07-05
EP1663309A2 (en) 2006-06-07
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
ZA200602738B (en) 2008-06-25
NO20061184L (no) 2006-06-01
WO2005023303A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
US20090232798A1 (en) Methods and compositions for treating herpes infections
CA1254510A (en) Fibronectin preparations
BG60544B1 (en) Antiviral and antibacterial preparation and method for its usage
US4462986A (en) Synergistic anti-herpes compositions
Colin et al. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir
EP0382551A2 (en) Prevention and treatment of herpes virus infections
WO1995008998A1 (en) Compositions for the prevention and treatment of viral-induced tumors
Vilcek et al. Interferon induction by vesicular stomatitis virus and its role in virus replication
CN111249288B (zh) 甘露葡萄糖醛酸寡糖及其衍生物在制备治疗和/或预防hcmv药物中的应用
MXPA06002585A (en) Methods and compositions for treating herpes infections
JP4580479B2 (ja) 抗ｈｉｖ感染症剤
CN116850189B (zh) 普拉曲沙在制备治疗hsv所致疾病的药物中的用途
US5283239A (en) Inhibitor of herpesvirus absorption
JP3266254B2 (ja) ヘルペス関連疾患の治療方法および組成物
US4230725A (en) Antiviral agent
RU2847403C1 (ru) Способ лечения иммунодефицита внутривенным введением аминодигидрофталазиндиона натрия
KR20010108040A (ko) 항-ｈｉｖ 감염증제 및 ｈｉｖ 감염증의 치료 방법
CN116672346B (zh) 普拉曲沙在制备治疗vzv所致疾病的药物中的用途
US6495678B1 (en) Immunosuppressant containing glucopyranose derivative as active ingredient
CA2008911C (en) Process for preparing ethyl 6-bromo-5-hydroxy-4- dimethylaminomethyl-1-methyl-2-phenylthiomethylindole-3- carboxylate hydrochloride monohydrate and a pharmaceutical preparation containing the same having the antiviral, interferon-inducing and immunomodulatory effects
Vilas et al. Effect of a Uridine 5′-Diphosphate Glucose Analogue, on Herpes simplex keratitis in Rabbits and Vaginal Infection, in Guinea Pigs
WO2021210851A1 (ko) 태반추출물을 포함하는 항바이러스 조성물
JPH0977684A (ja) 自己免疫抑制性ｔ細胞の活性化剤
Nicholson Antiviral Therapy: Respiratory Infections, Genital Herpes, and Herpetic Keratitis
Chowchuvech et al. The influence of polyinosinic-polycytidylic acid complex on vaccinia keratitis in rabbits

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed